NanoBEO is an innovative and patented health technology based on nanotechnology to release bergamot essential oil (BEO) deprived of bergapten, to avoid phototoxicity typical of psoralens. The formulation is deviced to be contained in an airless dispenser, which allows the administration of a known dose of the formulation and has the appearance of a cream. The dosage is extremely simple to deliver as it is sufficient to administer the product to the patient’s two forearms and massage for a few minutes. The nanotechnological structure allows for the elimination of the odor and volatility of the main components. Preclinical and translational studies carried out so far have demonstrated that BEO modulates synaptic level of neurotransmitters in the central nervous syhstem (CNS), coincident with behavioural and analgesic effects. In fact, the established anxiolytic, flumazenil-insensitive, effect of BEO and the morphine doserescue effect are largely documented. Furthermore, the absence of aroma allows for the generation of solid double-blind evidence for clinical studies and to avoid aversive, non reproducible psychological effects, especially in dysosmic patients (a common situation in AD patients). The solution provided by NanoBEO offers the first needoriented treatment for agitation, a help seeking behaviour often triggered by undisclosed pain in patients with severe dementia. The latter can be administered easily by all caregivers in patients own homes and in nursing homes; it is safe for elderly patients, even those undergoing multiple treatments, and those in paraphysiological conditions. It is effective and usable over the long term. In conclusion, NanoBEO represents a public-worth innovation in the neglected area of severe dementia, marking a significant advancement in the history of the disease, moving from academic research to product development.
Characteristics of “NanoBEO” a Health Technology for the control of agitation, a help seeking behaviour often triggered by undisclosed pain, in severely demented patients
Giacinto Bagetta
2025-01-01
Abstract
NanoBEO is an innovative and patented health technology based on nanotechnology to release bergamot essential oil (BEO) deprived of bergapten, to avoid phototoxicity typical of psoralens. The formulation is deviced to be contained in an airless dispenser, which allows the administration of a known dose of the formulation and has the appearance of a cream. The dosage is extremely simple to deliver as it is sufficient to administer the product to the patient’s two forearms and massage for a few minutes. The nanotechnological structure allows for the elimination of the odor and volatility of the main components. Preclinical and translational studies carried out so far have demonstrated that BEO modulates synaptic level of neurotransmitters in the central nervous syhstem (CNS), coincident with behavioural and analgesic effects. In fact, the established anxiolytic, flumazenil-insensitive, effect of BEO and the morphine doserescue effect are largely documented. Furthermore, the absence of aroma allows for the generation of solid double-blind evidence for clinical studies and to avoid aversive, non reproducible psychological effects, especially in dysosmic patients (a common situation in AD patients). The solution provided by NanoBEO offers the first needoriented treatment for agitation, a help seeking behaviour often triggered by undisclosed pain in patients with severe dementia. The latter can be administered easily by all caregivers in patients own homes and in nursing homes; it is safe for elderly patients, even those undergoing multiple treatments, and those in paraphysiological conditions. It is effective and usable over the long term. In conclusion, NanoBEO represents a public-worth innovation in the neglected area of severe dementia, marking a significant advancement in the history of the disease, moving from academic research to product development.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
